封面
市場調查報告書
商品編碼
1197888

胰腺和膽道支架市場 - 增長、趨勢和預測 (2023-2028)

Pancreatic and Biliary Stents Market - Growth, Trends and Forecasts (2023 - 2028)

出版日期: | 出版商: Mordor Intelligence | 英文 115 Pages | 商品交期: 2-3個工作天內

價格

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

簡介目錄

預計胰腺和膽道支架市場在預測期內的複合年增長率為 6.05%。

COVID-19 大流行的爆發影響了全球醫療保健系統和膽道支架市場。 例如,2021 年 10 月發表在學術期刊 WJCC 上的一篇論文報導,內窺鏡 ERCP 和經皮 PTC 手術與高病毒感染率相關。 因此,最初,由於感染上升、政府限制導致非緊急外科手術(包括 ERCP 和 PTC 手術)暫停,大量 COVID-19 病例影響了監測市場的增長。 然而,由於 COVID-19感染率下降以及 ERCP 和其他外科手術的恢復,預計未來幾年對膽道支架的需求將增加,預計市場將在預測期內出現顯著增長。

推動這一市場增長的因素包括胰腺癌和膽道疾病患病率的增加、支架和超聲內鏡技術的進步,以及微創手術的普及。 例如,根據Globocan 2020報告,2025年全球將有13.25萬膽囊癌患者,預計到2030年將增加到15.09萬,2040年將增加到19萬。我來了。 膽管癌是由阻塞膽管的腫大腫瘤引起的。 因此,膽囊癌負擔的增加有望推動市場增長。 同樣,2022 年 8 月發表在 AHPS 雜誌上的一篇論文報導了韓國膽囊癌、肝外膽管癌和胰腺癌的高發病率和穩步上升的死亡率。 因此,預計膽囊癌的高患病率將推動對膽道支架的需求,從而推動預測期內監測市場的增長。

此外,隨著消化道手術新技術的引入,如生物可吸收支架和自膨脹金屬支架(SEMS),使用支架治療胰腺和膽道疾病的應用越來越普及。 例如,2021 年 10 月,波士頓科學公司獲得了美國 FDA 510(k) 許可和 CE 標誌,可以銷售 Advanix 膽道塑料支架。 因此,此類產品的推出正在推動所研究市場的增長。 此外,與開放手術相比,微創手術 (MIS) 的風險較低,因此越來越受歡迎,這導致人們更喜歡 MIS 而不是傳統手術,從而推動了研究市場的增長。

因此,由於胰腺癌和膽道疾病患病率的增加、支架和內窺鏡技術的進步以及微創手術的日益普及,預計胰腺和膽道市場在預測期內將會增長。 然而,對與程序複雜性和嚴格的政府法規相關的高成本的擔憂可能會在預測期內減緩所研究市場的增長。

胰腺/膽道支架市場趨勢

金屬胰腺和膽道支架預計在預測期內將顯著增長。

金屬支架是由細線製成的自膨脹網狀管,插入體腔或導管以保持膽管和胰管暢通。 由於使用各種金屬支架治療各種胰腺和膽道相關疾病,如胰腺癌、胰腺/膽道滲漏和其他惡性梗阻,預計該領域將顯著增長。 此外,全球範圍內前列腺癌發病率的增加也大大促進了金屬支架的發展。 例如,2022年ACS報告稱,美國前列腺癌病例已達26.85萬例,比過去三年增長了12.5%。 因此,大量的前列腺癌病例推動了對其治療的金屬支架的需求,從而推動了這一細分市場的增長。

與金屬支架應用相關的不斷增加的研究和臨床研究也在推動這一領域的增長。 例如,2022 年 5 月發表在《科學報告》(Scientific Reports) 上的一篇論文指出,一項臨床研究報告稱,使用完全包裹的自膨脹金屬支架成功治療了良性膽道結構 (BBS)。 因此,這種有希望的結果導致對金屬支架的需求增加,從而推動了這一領域的增長。

此外,新產品的開發和更好的技術正在加強胰腺和膽道市場。 例如,2021 年 5 月,AMG International GmbH 為其第二個完全可生物降解的金屬支架 UNITY-B 啟動了 CE 標誌批准,這是一種內窺鏡球囊擴張可生物降解膽道支架 (BEBS)。 該產品發布的目的是增強我們的產品陣容並增加我們在市場上的影響力。

由於各種金屬支架廣泛用於治療與胰腺和膽道相關的各種疾病,預計該細分市場將在未來幾年顯著擴大,並在整個預測期內推動市場發展。

北美預計在預測期內將顯著增長。

北美正在經歷強勁的增長,醫療行業成熟,前列腺癌、胰腺癌和膽囊癌等慢性病患病率上升,推動了對胰腺和膽道支架的需求。預計將顯示 例如,2022 年 ACS 報告男性胰腺癌新發病例為 32.9 千例,而女性為 29.2 萬例。 同樣,2022 年 1 月的 CAGS 報告了加拿大膽囊癌的高患病率。 因此,北美國家胰腺癌和膽囊癌患病率上升正在刺激胰腺支架研究市場的擴張。

此外,最近的兼併、收購和合作夥伴關係進一步推動了該細分市場的增長。 例如,2021 年 5 月,庫克醫療收購了 Cantel Medical,擴大了其膽道支架和其他產品組合,以服務全球客戶。 因此,該地區的此類發展可能會增加對胰腺和膽道支架的需求。 同樣,在 2022 年 7 月,CDC 報告稱,僅在 2021 年,美國就有 450 萬成年人被診斷患有慢性肝病,佔該國患有該病的成年人總數的 1.8%。 當肝臟炎症阻塞膽管時,必須放置膽道支架以緩解阻塞。 這增加了對膽道支架的需求,並促進了該地區研究市場的增長。

該地區擁有發達的醫療保健行業,前列腺癌、胰腺癌和膽囊癌等慢性病發病率上升,這些疾病可能會在預測期內提振市場並實現顯著增長。被認為是高風險。

胰腺和膽道支架市場的競爭對手分析

由於市場進入者的多樣性,全球胰腺和膽道支架市場競爭適中。 目前,只有少數幾家公司佔據了相當大的市場份額。 預計在整個預測期內,幾家區域性公司將進入胰腺和膽道支架市場。 這是由於患者意識水平的提高和疾病的高患病率。 市場上的主要參與者包括波士頓科學公司、庫克醫療公司、CONMED 公司、奧林巴斯公司、Becton、Dickinson and Company、雅培實驗室、美敦力公司、史賽克公司、泰宇醫療等。

其他福利。

  • Excel 格式的市場預測 (ME) 表
  • 3 個月的分析師支持

內容

第1章介紹

  • 研究假設和市場定義
  • 調查範圍

第2章研究方法論

第 3 章執行摘要

第4章市場動態

  • 市場概覽
  • 市場驅動因素
    • 胰腺癌和膽道疾病增加
    • 支架和內窺鏡技術的進步
    • 微創手術越來越受歡迎
  • 市場製約因素
    • 與手術相關的高成本和復雜性
    • 嚴格的政府法規
  • 波特的五力分析
    • 新進入者的威脅
    • 買方/消費者議價能力
    • 供應商的議價能力
    • 替代品的威脅
    • 競爭公司之間的敵對關係

第 5 章市場細分(基於價值的市場規模:百萬美元)

  • 按產品類型
    • 塑料支架
    • 金屬支架
  • 通過申請
    • 良性膽道結構
    • 膽汁/胰液滲漏
    • 胰腺癌
    • 其他用途
  • 最終用戶
    • 醫院
    • 門診手術中心
    • 其他最終用戶
  • 按地區
    • 北美
      • 美國
      • 加拿大
      • 墨西哥
    • 歐洲
      • 德國
      • 英國
      • 法國
      • 意大利
      • 西班牙
      • 其他歐洲地區
    • 亞太地區
      • 中國
      • 日本
      • 印度
      • 澳大利亞
      • 韓國
      • 其他亞太地區
    • 中東
      • 海灣合作委員會
      • 南非
      • 其他中東地區
    • 南美洲
      • 巴西
      • 阿根廷
      • 其他南美洲

第6章競爭格局

  • 公司簡介
    • Boston Scientific Corporation
    • Cook Medical Inc
    • CONMED Corporation
    • Olympus Corporation
    • Becton, Dickinson and Company
    • Abbott Laboratories
    • Medtronic Plc
    • Stryker Corporation
    • Taewoong Medical Co., Ltd.
    • Endo-Flex GmbH
    • B. Braun Melsungen AG
    • Cardinal Health

第7章 市場機會與今後動向

簡介目錄
Product Code: 72223

The pancreatic and biliary stents market is expected to register a CAGR of 6.05%, over the forecast period.

The outbreak of the COVID-19 pandemic impacted the global healthcare system and the biliary stents market. For instance, an article published in the journal WJCC, in October 2021, reported that endoscopic ERCP and percutaneous PTC procedures were associated with high rates of viral transmission. Thus, initially, the high number of COVID-19 cases led to increased transmission of infections that led to the suspension of non-emergency surgical procedures including ERCP and PTC procedures, imposed by the government restrictions which impacted the growth of the studied market. However, in the upcoming years, it is anticipated that declining COVID-19 infection rates and the resumption of ERCP and other surgical procedures may increase the demand for the biliary stent, and thus the market is expected to witness significant growth over the forecast period.

The factors that are driving the growth of this market are an increase in the prevalence of pancreatic cancer and biliary duct diseases, technological advancements in stents and endosonographic, and the increasing popularity of minimally invasive surgery. For instance, according to the Globocan 2020 report, globally 132.5 thousand gallbladder cancer cases will be recorded in 2025, and this number is expected to increase to 150.9 thousand by 2030 and to 190 thousand by 2040. Bile duct cancer can lead to the enlargement of a tumor blocking the bile duct. Hence, the placement of a biliary stent can assist in the optimum drainage of the bile; hence, the rising burden of gallbladder cancer is expected to boost market growth. Similarly, an article published by the journal AHPS, in August 2022, reported that high incidence and mortality rates of gallbladder, extrahepatic bile duct, and pancreatic cancer are steadily increasing in Korea. Thus, a high prevalence of gallbladder cancer is expected to drive the demand for biliary stents, thereby driving the growth of the studied market over the forecast period.

Furthermore, with the introduction of new technologies for gastrointestinal surgeries such as bioabsorbable stents and self-expanding metal stents (SEMS), the use of stents for the treatment of pancreatic and biliary diseases is gaining popularity. For instance, in October 2021, Boston Scientific received the 510 (k) US FDA clearance and CE mark approval to market its Advanix biliary plastic stents. Thus, such product launches are driving the growth of the studied market. Moreover, the increasing popularity of minimally invasive surgery (MIS) due to the low risk associated with it compared to open surgeries is increasing the preference for MIS over normal surgeries and thus, fueling the growth of the studied market.

Therefore, due to the increase in the prevalence of pancreatic cancer and biliary duct diseases, technological advancements in stents and endosonography, and increasing popularity of minimally invasive surgery, the pancreatic and biliary market is anticipated to grow over the forecast period. However, the concerns regarding the high cost associated with procedural complexities, and stringent government regulations may slow down the growth of the studied market over the forecast period.

Pancreatic & Biliary Stents Market Trends

Metal Pancreatic and Biliary Stents is Expected to Witness a Significant Growth Over the Forecast Period.

Metal stents are self-expandable mesh-like tubes of thin wire which are inserted into a lumen or duct in the human body to maintain the passage open in the bile or pancreatic duct. The segment is expected to witness significant growth owing to the wide application of a range of metal stents for the treatment of various pancreatic and biliary-related diseases such as pancreatic cancer, pancreatic and biliary leaks, and other malignant obstructions. Moreover, the increase in the number of prostate cancers worldwide has significantly aided in the growth of metallic stents. For instance, in 2022 ACS, reported a 12.5% increase in prostate cancer cases in the US over the last three years reaching 268.5 thousand prostate cancer cases in 2022. Thus, the high number of prostate cancer cases is driving the demand for metallic stents for its treatment thereby driving the growth of this segment.

The increasing research and clinical studies related to applications of metallic stents are also propelling the growth of this segment. For instance, an article published by the journal Scientific Reports, in May 2022, stated that a clinical study reported the successful treatment of benign biliary structures (BBS) using fully covered self-expandable metal stents. Thus, such promising results are leading to the increasing demand for metallic stents thereby driving the growth of the segment.

Furthermore, new products and the development of better technology have bolstered the pancreatic and biliary market. For instance, in May 2021, AMG International GmbH launched the CE mark approval of their second fully biodegradable metal stent UNITY-B, which is a balloon expandable biodegradable biliary stent (BEBS) for endoscopic use. This product launch was aimed at expanding the company's product offering as well as enhancing its market presence.

Thereby, the sector is anticipated to experience significant expansion, thus driving the market throughout the forecast period, thanks to the widespread application of a variety of metal stents for the treatment of various pancreatic and biliary-related illnesses.

North America Region is Expected to Witness a Significant Growth Over the Forecast Period.

North America is expected to witness significant growth owing to the well-established healthcare industry and the rising prevalence of chronic diseases like prostate cancer, pancreatic cancer, and gall bladder cancer which is increasing the demand for pancreatic and biliary stents. For instance, ACS in 2022, reported 32.9 thousand new pancreatic cancer cases in men compared to 29.2 thousand pancreatic cancer cases in women in the United States. Similarly, CAGS in January 2022, reported the high prevalence of gallbladder cancer in Canada. As a result, the rising prevalence of pancreatic and gallbladder cancers in North American countries is fueling the expansion of the examined market for pancreatic stents.

Furthermore, the recent mergers, acquisitions, and partnerships are further driving the growth of this segment. For instance, in May 2021, Cook Medical acquired Cantel Medical to expand its biliary stent and another product portfolio to provide services to customers globally. Thus, such development in the region is likely to boost the demand for pancreatic and biliary stents. Similarly, in July 2022, CDC reported that in 2021, 4.5 million adults were diagnosed with chronic liver disease in the United States alone which contributed to 1.8% of the country's total adult population diagnosed with the disease. When liver inflammation results in bile duct blockage, a biliary stent must be implanted to relieve the obstruction. This drives up demand for biliary stents and contributes to the growth of the studied market in the region.

Thus, the region is likely to have considerable growth, boosting the market throughout the forecast period, on account of its well-established healthcare industry and the rising prevalence of chronic diseases such as prostate cancer, pancreatic cancer, and gall bladder cancer.

Pancreatic & Biliary Stents Market Competitor Analysis

The global market for pancreatic and biliary stents is moderately competitive, with a number of different market participants. Currently, only a handful of companies hold a sizable percentage of the market share. It is anticipated that several regional players would participate in the pancreatic and biliary stents market throughout the projection period. This is due to the increasing patient awareness levels and high prevalence of diseases.Some of the key players in the market are Boston Scientific Corporation, Cook Medical Inc, CONMED Corporation, Olympus Corporation, Becton, Dickinson and Company, Abbott Laboratories, Medtronic Plc, Stryker Corporation, and Taewoong Medical Co., Ltd., among others.

Additional Benefits:

  • The market estimate (ME) sheet in Excel format
  • 3 months of analyst support

TABLE OF CONTENTS

1 INTRODUCTION

  • 1.1 Study Assumptions and Market Definition
  • 1.2 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS

  • 4.1 Market Overview
  • 4.2 Market Drivers
    • 4.2.1 Increase in the Prevalence of Pancreatic Cancer and Biliary Duct Diseases
    • 4.2.2 Technological Advancements in Stents and Endosonography
    • 4.2.3 Increasing Popularity of Minimally Invasive Surgery
  • 4.3 Market Restraints
    • 4.3.1 High Cost and Complexity Associated with the Procedure
    • 4.3.2 Stringent Government Regulations
  • 4.4 Porter's Five Force Analysis
    • 4.4.1 Threat of New Entrants
    • 4.4.2 Bargaining Power of Buyers/Consumers
    • 4.4.3 Bargaining Power of Suppliers
    • 4.4.4 Threat of Substitute Products
    • 4.4.5 Intensity of Competitive Rivalry

5 MARKET SEGMENTATION (Market Size by Value - USD million)

  • 5.1 By Product Type
    • 5.1.1 Plastic Stents
    • 5.1.2 Metal Stents
  • 5.2 By Application
    • 5.2.1 Benign Biliary Structures
    • 5.2.2 Bilio-Pancreatic Leakages
    • 5.2.3 Pancreatic Cancer
    • 5.2.4 Other Applications
  • 5.3 By End Users
    • 5.3.1 Hospitals
    • 5.3.2 Ambulatory Surgical Centers
    • 5.3.3 Other End-Users
  • 5.4 Geography
    • 5.4.1 North America
      • 5.4.1.1 United States
      • 5.4.1.2 Canada
      • 5.4.1.3 Mexico
    • 5.4.2 Europe
      • 5.4.2.1 Germany
      • 5.4.2.2 United Kingdom
      • 5.4.2.3 France
      • 5.4.2.4 Italy
      • 5.4.2.5 Spain
      • 5.4.2.6 Rest of Europe
    • 5.4.3 Asia-Pacific
      • 5.4.3.1 China
      • 5.4.3.2 Japan
      • 5.4.3.3 India
      • 5.4.3.4 Australia
      • 5.4.3.5 South Korea
      • 5.4.3.6 Rest of Asia-Pacific
    • 5.4.4 Middle East
      • 5.4.4.1 GCC
      • 5.4.4.2 South Africa
      • 5.4.4.3 Rest of Middle East
    • 5.4.5 South America
      • 5.4.5.1 Brazil
      • 5.4.5.2 Argentina
      • 5.4.5.3 Rest of South America

6 COMPETITIVE LANDSCAPE

  • 6.1 Company Profiles
    • 6.1.1 Boston Scientific Corporation
    • 6.1.2 Cook Medical Inc
    • 6.1.3 CONMED Corporation
    • 6.1.4 Olympus Corporation
    • 6.1.5 Becton, Dickinson and Company
    • 6.1.6 Abbott Laboratories
    • 6.1.7 Medtronic Plc
    • 6.1.8 Stryker Corporation
    • 6.1.9 Taewoong Medical Co., Ltd.
    • 6.1.10 Endo-Flex GmbH
    • 6.1.11 B. Braun Melsungen AG
    • 6.1.12 Cardinal Health

7 MARKET OPPORTUNITIES AND FUTURE TRENDS